Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1201927 | 0.94 | CHRM5 (0.37) | RAD52RECQL | |
| SCHEMBL1202584 | 0.93 | CHRM5 (0.40) | — | |
| SCHEMBL1202027 | 0.76 | GRM5 (0.40) | RAD52RECQLGRM5 | |
| SCHEMBL209145 | 0.75 | HSD17B10 (0.36) | RAD52RECQL | |
| SCHEMBL1201992 | 0.75 | GRM5 (0.48) | RAD52RECQLGRM5 | |
| SCHEMBL1202784 | 0.73 | GRM5 (0.50) | RAD52RECQLGRM5 | |
| SCHEMBL1201616 | 0.73 | RAB9A (0.49) | — | |
| SCHEMBL1202801 | 0.73 | RAD52 (0.36) | RAD52RECQLGRM5 | |
| SCHEMBL208726 | 0.72 | GRM5 (0.36) | GRM5 | |
| SCHEMBL17088068 | 0.71 | RAD52 (0.47) | RAD52RECQLGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | RAD52 4693/4885RECQL 3081/4885PDE1B 1187/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | RAD52 4693/4885RECQL 3081/4885PDE1B 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.